A method for preventing and/or treating tremors, comprising a step of administering a drug or a healthcare product to a subject in need, wherein the drug or the healthcare product comprises one or more of a Ginkgo biloba terpene lactone compound or a pharmaceutically acceptable salt, ester, hydrate, solvate, or isomer thereof, or any crystal form, racemate, or metabolite of same, or a mixture of same as an active ingredient;
- wherein the Ginkgo biloba terpene lactone compound is selected from a compound of formula (I), a compound of formula (II) or a compound of formula (III);
- wherein the compound of formula (I) has a structure of:
- wherein, in the compound of formula (I), R1 is selected from the group consisting of H, CH3, CH2CH3, CH2Ph, COCH3 and SO2CH3, and R2 is selected from the group consisting of H, CH3, CH2CH3, CH2Ph, COCH3 and SO2CH3;
- wherein the compound of formula (II) has a structure of:
- wherein, in the compound of formula (II), R1 is selected from the group consisting of H and OH, R2 is selected from the group consisting of OH and H, R3 is selected from the group consisting of H and OH, R4 is selected from the group consisting of OH and H, and R5 is selected from the group consisting of H, CH3, CH2CH3, CH2Ph, COCH3, SO2CH3, OH, H2PO3, H2SO3, —CH2—Ar, —CH2CH2—Ar, —CH2CH2CH2—Ar, —CONH—Ar, —CH2O—Ar, —CH2CH2O—Ar, —CH2CH2CH2O—Ar, —CO—Ar, —SO2—Ar and —CO-A-Ar,
- wherein A is C2-C8 alkenylene unsubstituted or substituted with C1-C6 alkyl, and wherein Ar is one or more selected from the group consisting of phenyl, pyridyl, pyrimidinyl, quinolyl or pyrazinyl, unsubstituted or substituted with 1-5 substituents selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, carboxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 acyloxy, C1-C6 ester group, C1-C10 alkyl, C1-C10 haloalkane, C1-C10 alkoxy, C1-C10 halogenated alkoxy, phenyl, phenoxy, aralkyl, aralkyloxy, —COR6, —CONR6R7, —CO2R6, —CH2OR6, —NR6R7, —CH2NR6R7, —CN and —NO2;
- and
- wherein R6 is selected from the group consisting of hydrogen, C1-C10 alkyl, C3-C10 cycloalkyl, phenyl, pyridyl, pyrimidinyl, quinolyl and pyrazinyl, and R7 is selected from the group consisting of hydrogen, C1-C10 alkyl, C3-C10 cycloalkyl, phenyl, pyridyl, pyrimidinyl, quinolyl and pyrazinyl;
- and
- wherein the compound of formula (III) has a structure of:
- wherein, in the compound of formula (III), R1 is selected from the group consisting of H and OH, R2 is selected from the group consisting of OH and H, and R3 is selected from the group consisting of H, CH3, CH2CH3, CH2Ph, COCH3, SO2CH3, OH, H2PO3, H2SO3, —CH2—Ar, —CH2CH2—Ar, —CH2CH2CH2—Ar, —CONH—Ar, —CH2O—Ar, —CH2CH2O—Ar, —CH2CH2CH2O—Ar, —CO—Ar, —SO2—Ar and —CO-A-Ar,
- wherein A is C2-C8 alkenylene unsubstituted or substituted with C1-C6 alkyl, and Ar is one or more selected from the group consisting of phenyl, pyridyl, pyrimidinyl, quinolyl or pyrazinyl, unsubstituted or substituted with 1-5 substituents selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, carboxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 acyloxy, C1-C6 ester group, C1-C10 alkyl, C1-C10 haloalkane, C1-C10 alkoxy, C1-C10 halogenated alkoxy, phenyl, phenoxy, aralkyl, aralkyloxy, —COR6, —CONR6R7, —CO2R6, —CH2OR6, —NR6R7, —CH2NR6R7, —CN and —NO2;
- and
- wherein R6 is selected from the group consisting of hydrogen, C1-C10 alkyl, C3-C10 cycloalkyl, phenyl, pyridyl, pyrimidinyl, quinolyl and pyrazinyl, and R7 is selected from the group consisting of hydrogen, C1-C10 alkyl, C3-C10 cycloalkyl, phenyl, pyridyl, pyrimidinyl, quinolyl and pyrazinyl.